Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC decreased its holdings in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 33.0% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 51,974 shares of the biopharmaceutical company's stock after selling 25,550 shares during the quarter. SG Americas Securities LLC's holdings in Dynavax Technologies were worth $674,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of DVAX. Russell Investments Group Ltd. lifted its holdings in Dynavax Technologies by 96.5% in the 4th quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 1,169 shares in the last quarter. Smartleaf Asset Management LLC lifted its stake in shares of Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 2,034 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Dynavax Technologies during the fourth quarter worth about $35,000. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in Dynavax Technologies during the 4th quarter valued at about $71,000. Finally, GAMMA Investing LLC raised its holdings in Dynavax Technologies by 88.4% in the 1st quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company's stock valued at $100,000 after acquiring an additional 3,627 shares during the last quarter. Hedge funds and other institutional investors own 96.96% of the company's stock.

Dynavax Technologies Trading Up 1.4%

DVAX traded up $0.14 on Tuesday, hitting $9.91. The company had a trading volume of 1,102,482 shares, compared to its average volume of 2,168,586. The company has a current ratio of 11.93, a quick ratio of 10.84 and a debt-to-equity ratio of 0.49. The firm has a market cap of $1.19 billion, a P/E ratio of -19.06 and a beta of 1.07. The company's fifty day moving average price is $10.26 and its 200 day moving average price is $12.04. Dynavax Technologies Corporation has a 1 year low of $9.22 and a 1 year high of $14.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.14). Dynavax Technologies had a positive return on equity of 3.59% and a negative net margin of 20.39%. The company had revenue of $68.16 million during the quarter, compared to analyst estimates of $70.01 million. As a group, equities analysts expect that Dynavax Technologies Corporation will post 0.32 earnings per share for the current year.

Analyst Ratings Changes

DVAX has been the topic of several recent research reports. The Goldman Sachs Group lowered their target price on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a report on Thursday, April 17th. Wall Street Zen cut shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a research report on Tuesday, May 6th. Finally, JMP Securities cut their price objective on shares of Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating for the company in a research report on Wednesday, May 7th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $24.00.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.